RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+49.6%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.26B
AUM Growth
+$1.26B
(+20%)
Cap. Flow
-$31.7M
Cap. Flow
% of AUM
-2.52%
Top 10 Holdings %
Top 10 Hldgs %
54.98%
Holding
68
New
14
Increased
7
Reduced
27
Closed
17
Top Buys
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$72.5M |
| 2 |
Puma Biotechnology
PBYI
|
$44.4M |
| 3 |
Sarepta Therapeutics
SRPT
|
$39.3M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$39M |
| 5 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$29.3M |
Top Sells
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
$56.1M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$37.8M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$26.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$25.1M |
| 5 |
Brookdale Senior Living
BKD
|
$23.9M |
Sector Composition
| 1 | Healthcare | 92.15% |
| 2 | Communication Services | 1.37% |
| 3 | Consumer Staples | 0.51% |
| 4 | Technology | 0% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MODN
26
DELISTED
MODEL N, INC.
MODN
| $17.2M | 1.37% |
1,550,959
-349,700
| -18% | -$3.89M |
|
|
BOLD
27
DELISTED
Audentes Therapeutics, Inc
BOLD
| $14.9M | 1.19% |
+916,626
| New | +$14.9M |
|
|
NDRM
28
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $14.9M | 1.18% |
805,246
-16,199
| -2% | -$300K |
|
|
SYRS
29
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $11.7M | 0.93% |
892,782
-53,400
| -6% | -$702K |
|
30
CytomX Therapeutics
CTMX
$345M
| $11.2M | 0.89% |
714,692
-19,207
| -3% | -$301K |
|
31
Charles River Laboratories
CRL
$7.91B
| $10.6M | 0.84% |
127,106
-4,500
| -3% | -$375K |
|
32
AstraZeneca
AZN
$253B
| $9.48M | 0.75% |
+288,356
| New | +$9.48M |
|
|
SPNC
33
DELISTED
Spectranetics Corp
SPNC
| $8.4M | 0.67% |
334,741
-67,095
| -17% | -$1.68M |
|
34
Ironwood Pharmaceuticals
IRWD
$192M
| $6.49M | 0.52% |
408,462
-34,249
| -8% | -$544K |
|
|
WOOF
35
DELISTED
VCA Inc.
WOOF
| $6.37M | 0.51% |
91,000
-3,200
| -3% | -$224K |
|
|
ALXN
36
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $5.57M | 0.44% |
45,410
-156,990
| -78% | -$19.2M |
|
|
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.13M | 0.41% |
336,759
-634,806
| -65% | -$9.67M |
|
|
NVTA
38
DELISTED
Invitae Corporation
NVTA
| $4.47M | 0.36% |
510,369
-34,570
| -6% | -$303K |
|
39
Fate Therapeutics
FATE
$115M
| $4.45M | 0.35% |
1,425,158
-77,022
| -5% | -$240K |
|
40
ProQR Therapeutics
PRQR
$255M
| $3.84M | 0.31% |
575,863
-5,775
| -1% | -$38.5K |
|
|
BPMC
41
DELISTED
Blueprint Medicines
BPMC
| $818K | 0.07% |
27,539
-814
| -3% | -$24.2K |
|
42
Aurinia Pharmaceuticals
AUPH
$1.57B
| $565K | 0.04% |
187,610
+159,200
| +560% | +$479K |
|
43
First Trust NYSE Arca Biotechnology Index Fund
FBT
$1.07B
| $308K | 0.02% |
+3,090
| New | +$308K |
|
44
UnitedHealth
UNH
$277B
| $255K | 0.02% |
+1,820
| New | +$255K |
|
45
Humana
HUM
$37.4B
| $246K | 0.02% |
+1,390
| New | +$246K |
|
46
DexCom
DXCM
$29.9B
| $216K | 0.02% |
+2,460
| New | +$216K |
|
47
Biogen
BIIB
$20.9B
| $212K | 0.02% |
677
-552
| -45% | -$173K |
|
|
AKAO
48
DELISTED
Achaogen, Inc.
AKAO
| $155K | 0.01% |
+32,300
| New | +$155K |
|
49
Adverum Biotechnologies
ADVM
$66.5M
| $91K | 0.01% |
22,236
| – | – |
|
|
CSLT
50
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $43K | ﹤0.01% |
10,229
| – | – |
|